Advertisement
U.S. markets closed

BioStem Technologies, Inc. (BSEM)

Other OTC - Other OTC Delayed Price. Currency in USD
9.15-0.09 (-0.97%)
At close: 03:47PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.24
Open9.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.04 - 9.25
52 Week Range1.20 - 10.60
Volume9,088
Avg. Volume27,766
Market Cap119.866M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.73
Earnings DateApr 01, 2024 - Apr 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BSEM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BIOSTEM TECHNOLOGIES INC
    Daily – Vickers Top Buyers & Sellers for 03/30/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Zacks Small Cap Research

    BSEM: Investors Need to Pay Attention to BSEM

    By Brad Sorensen, CFA OTC:BSEM READ THE FULL BSEM RESEARCH REPORT BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most effective regenerative medicine

  • GlobeNewswire

    Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

    BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for

  • GlobeNewswire

    BioStem Technologies Appoints Proven Life Science Sales Leader Shawn McCarrey to Chief Commercial Officer Role

    Mr. McCarrey brings a strong track record of success and deep experience in regenerative medicine marketsPOMPANO BEACH, Fla., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer. BioStem Technologies CEO